Speakers
Kimberly Aardalen
Scientific Technical Leader
Novartis Institutes for Biomedical Research
Thomas Schürpf
Senior Director, Tumor Biology
Parthenon Therapeutics
Day Two
Thursday, July 15, 2021
3:45 pm | Breaking Down Barriers In Immune-Excluded Tumor Biology
Khalid Shah
Vice Chairman at BWH
Harvard Medical School
Day One
Wednesday, July 14, 2021
9:30 am | Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors
Agnieszka Denslow
Associate Director
Pharmacology / Toxicology, Oncorus
Day Two
Thursday, July 15, 2021
8:30 am | Modelling Small Cell Lung Cancer in Preclinical Development of Synthetic Oncolytic Virus
Beatrice Wang
Associate Director
IGM Biosciences
Day One
Wednesday, July 14, 2021
8:30 am | Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo
Frank Sun
Senior Principal Scientist, Oncology Pharmacology
Sanofi
Preclinical Track - Day 1 am
11:45 am | Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology
Jessica Haverkamp
Associate Director Macrophage Biology
BlueRock Therapeutics
Day One
Wednesday, July 14, 2021
4:30 pm | Chair’s Closing Remarks & End of Conference Day One
8:20 am | Chair’s Opening Remarks
Preclinical Track - Day 1 am
11:15 am | Panel Discussion: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification
Jingjing Jiang
Senior Director, Translational Research
Revolution Medicines
Translation Track - Day 1 am
11:45 am | Combination Therapy to Outsmart RASAddicted Cancer - Informing Clinical Strategy with Preclinical Modeling
Natalia Blanco
Associate Director, Immuno-Oncology
Morphic Therapeutics
Drug Discovery Track - Day 2 pm
1:15 pm | Treatment Modalities to Improve Response in Tumors Refractory to Standard Immunotherapy Approaches
Katie Grausam
Postdoctoral Scientist
Cedars Sinai
Day Two
Thursday, July 15, 2021
11:15 am | Weighing up Pros & Cons of Quick & Dirty Models Versus Slower Growing Models
3:15 pm | Panel Discussion - What Are the Advantages of 3D Models
Ludovic Bigot
Project Manager
Gustav Rousey
Drug Development Track - Day 2 pm
2:15 pm | Panel Discussion: Resistance Versus Sensitivity of the Drug Towards the Tumor
1:45 pm | MATCH-R: A Preclinical Platform of Resistant Models to Innovative Therapies • Highlighting the development of a panel
Marc Pelletier
Senior Principal Scientist
Novartis
Preclinical Track - Day 1 am
11:15 am | Panel Discussion: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification
Marc Zuckermann
Group Leader Preclinical Modeling
German Cancer Research Center (DKFZ)
Translation Track - Day 1 am
11:15 am | Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma
Johanna Lahdenranta
Director In Vivo Pharmacology
Bicycle Therapeutics
Drug Development Track - Day 2 pm
1:15 pm | Exploring Tumor Localized CD137 Agonism with Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs®)
Juan Arriaga
Assistant Professor – Department of Oncological Sciences & Urology
Icahn School of Medicine at Mount Sinai
Day One
Wednesday, July 14, 2021
1:45 pm | Modeling Bone Metastasis of Prostate Cancer
Day Two
Thursday, July 15, 2021
3:15 pm | Panel Discussion - What Are the Advantages of 3D Models
Scott Boiko
Associate Director Translational Science
Forma Therapeutics
Day Two
Thursday, July 15, 2021
9:15 am | Roundtable: Outlining Model Validation & Establishing the Need for Standardization
Anita Seshire
Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology
Merck EMD Serono
Day One
Wednesday, July 14, 2021
3:30 pm | Developing Clinically Translatable Models that Accurately Represent Patient Metastasis
Day Two
Thursday, July 15, 2021
3:15 pm | Panel Discussion - What Are the Advantages of 3D Models
Tomasz Owczarek
Senior Staff Scientist
Regeneron
Drug Discovery Track - Day 2 pm
2:15 pm | Model Selection for Tumor Heterogeneity & TME
Soner Altiok
CSO
Nilogen Oncosystems
Jon Waterman-Smith
Vice President Of Marketing & Business Development
Nilogen Oncosystems
Jun Zhang
MD, PhD, Associate Professor
University of Kansas Medical Center, Medical Oncology
Javier Pineda
Bioinformatics Lead
Scientist.com
Day Two
Thursday, July 15, 2021
12:00 pm | The Disease Model Finder: An AI-Powered Platform to Enhance Disease Model Sourcing
Marco Campisi
Postdoctoral Research Fellow
Dana-Farber Cancer Institute
Day Two
Thursday, July 15, 2021
3:15 pm | Panel Discussion - What Are the Advantages of 3D Models
Drug Discovery Track - Day 2 pm
1:45 pm | Retaining the Tumor Immune Microenvironment Heterogeneity & Vascular Cross-talks in Ex-Vivo Microphysiological Models
Gareth Griffiths
CSO
Imagen Therapeutics
Day One
Wednesday, July 14, 2021
10:00 am | Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle
Senior Representative
Hera BioLabs
Day Two
Thursday, July 15, 2021
11:45 am | Orthotopic & Metastatic Xenograft Studies in the SRG Rat
Monika Buczek, PhD
Director
Business Development
Day Two
Thursday, July 15, 2021
10:00 am | Translating Preclinical Combinatorial Therapy Approaches in In Vitro & In Vivo Models of Human Glioblastoma Multiforme
Shiva Kazerounian
Associate Director of in Vivo Pharmacology
Berg Health
Eric Ibsen
Chief Executive Officer
Studylog